CA2204277C - Combined meningitis vaccine - Google Patents
Combined meningitis vaccine Download PDFInfo
- Publication number
- CA2204277C CA2204277C CA002204277A CA2204277A CA2204277C CA 2204277 C CA2204277 C CA 2204277C CA 002204277 A CA002204277 A CA 002204277A CA 2204277 A CA2204277 A CA 2204277A CA 2204277 C CA2204277 C CA 2204277C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- conjugate
- meningitis
- neisseria meningitidis
- oligosaccharide conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940014135 meningitis vaccine Drugs 0.000 title claims description 7
- 229960005486 vaccine Drugs 0.000 claims abstract description 63
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 47
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 46
- 238000002255 vaccination Methods 0.000 claims abstract description 25
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 17
- 206010013023 diphtheria Diseases 0.000 claims abstract description 14
- 230000037452 priming Effects 0.000 claims abstract description 12
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 201000009906 Meningitis Diseases 0.000 claims abstract description 8
- 206010043376 Tetanus Diseases 0.000 claims abstract description 8
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 206010027202 Meningitis bacterial Diseases 0.000 claims abstract description 5
- 201000005702 Pertussis Diseases 0.000 claims abstract description 5
- 201000009904 bacterial meningitis Diseases 0.000 claims abstract description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 18
- 108010078791 Carrier Proteins Proteins 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 11
- 229960000814 tetanus toxoid Drugs 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 7
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 101710116435 Outer membrane protein Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 11
- 108091007433 antigens Proteins 0.000 abstract description 11
- 102000036639 antigens Human genes 0.000 abstract description 11
- 230000004044 response Effects 0.000 abstract description 6
- 229940001442 combination vaccine Drugs 0.000 abstract description 5
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 abstract 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 abstract 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 14
- 229940031670 conjugate vaccine Drugs 0.000 description 14
- 230000005875 antibody response Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 230000002096 anti-tetanic effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940032024 DPT vaccine Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940127241 oral polio vaccine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000116710 Ferula foetidissima Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- -1 N-hydroxysuccinimide diester Chemical class 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2689871A CA2689871A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422096.9 | 1994-11-02 | ||
| GB9422096A GB9422096D0 (en) | 1994-11-02 | 1994-11-02 | Combined meningitis vaccine |
| PCT/IB1995/001006 WO1996014086A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2689871A Division CA2689871A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2204277A1 CA2204277A1 (en) | 1996-05-17 |
| CA2204277C true CA2204277C (en) | 2010-02-02 |
Family
ID=10763774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002204277A Expired - Fee Related CA2204277C (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
| CA2689871A Abandoned CA2689871A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2689871A Abandoned CA2689871A1 (en) | 1994-11-02 | 1995-11-02 | Combined meningitis vaccine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6251401B1 (enExample) |
| EP (3) | EP1312377A3 (enExample) |
| JP (3) | JP3989951B2 (enExample) |
| AT (1) | ATE246936T1 (enExample) |
| CA (2) | CA2204277C (enExample) |
| CY (1) | CY2423B1 (enExample) |
| DE (1) | DE69531501T3 (enExample) |
| DK (1) | DK0789587T4 (enExample) |
| ES (1) | ES2204967T5 (enExample) |
| GB (1) | GB9422096D0 (enExample) |
| PT (1) | PT789587E (enExample) |
| WO (1) | WO1996014086A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US6048527A (en) * | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
| JP4162267B2 (ja) | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法 |
| EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| EP0983342B1 (en) * | 1997-05-28 | 2007-09-05 | Novartis Vaccines and Diagnostics S.r.l. | Culture medium with soy bean extract as aminoacid source and no protein complexes of animal origin |
| US20040087020A1 (en) | 1997-05-28 | 2004-05-06 | Chiron S.P.A. | Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin |
| US20070259007A1 (en) * | 1999-10-19 | 2007-11-08 | Kruzel Marian L | Lactoferrin: an adjuvant for vaccines |
| JP4948731B2 (ja) * | 1999-12-02 | 2012-06-06 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 凍結乾燥の際に生物学的分子を安定化するための組成物および方法 |
| EP2277541A1 (en) * | 2000-06-29 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| RU2322451C2 (ru) | 2001-04-17 | 2008-04-20 | Новартис Вэксинс Энд Диагностикс, Инк. | Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| DE60328481D1 (de) * | 2002-05-14 | 2009-09-03 | Novartis Vaccines & Diagnostic | Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält |
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| PT2191844E (pt) | 2003-01-30 | 2014-06-04 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| RU2378010C2 (ru) | 2003-10-02 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Жидкие вакцины для множественных серогрупп менингококков |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| WO2007000341A2 (en) | 2005-06-27 | 2007-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| NZ581367A (en) * | 2007-06-04 | 2012-05-25 | Novartis Ag | Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis |
| SI2200642T1 (sl) * | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
| JP2011506334A (ja) | 2007-12-07 | 2011-03-03 | ノバルティス アーゲー | 免疫応答を誘導するための組成物 |
| SI2608805T2 (sl) | 2010-08-23 | 2025-09-30 | Wyeth Llc | Stabilne formulacije antigenov rLP2086 neisserie meningitidis |
| BR112013005329A2 (pt) | 2010-09-10 | 2017-05-02 | Wyeth Llc | variantes não lipidadas de antígenos orf2086 de neisseria meningitidis |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX2018011291A (es) | 2012-03-09 | 2023-01-31 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4451446A (en) * | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5371197A (en) * | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US5628496A (en) | 1995-06-07 | 1997-05-13 | Avm, Inc. | Pneumatic spring |
| US6048527A (en) * | 1996-08-27 | 2000-04-11 | Chiron Corporation | Antibodies that define unique Meningococcal B epitopes and vaccine compositions |
-
1994
- 1994-11-02 GB GB9422096A patent/GB9422096D0/en active Pending
-
1995
- 1995-11-02 CA CA002204277A patent/CA2204277C/en not_active Expired - Fee Related
- 1995-11-02 EP EP03075069A patent/EP1312377A3/en not_active Withdrawn
- 1995-11-02 AT AT95935550T patent/ATE246936T1/de active
- 1995-11-02 JP JP51517596A patent/JP3989951B2/ja not_active Expired - Fee Related
- 1995-11-02 ES ES95935550T patent/ES2204967T5/es not_active Expired - Lifetime
- 1995-11-02 US US08/836,080 patent/US6251401B1/en not_active Expired - Lifetime
- 1995-11-02 CA CA2689871A patent/CA2689871A1/en not_active Abandoned
- 1995-11-02 PT PT95935550T patent/PT789587E/pt unknown
- 1995-11-02 EP EP10075114A patent/EP2204185A1/en not_active Withdrawn
- 1995-11-02 WO PCT/IB1995/001006 patent/WO1996014086A1/en not_active Ceased
- 1995-11-02 DE DE69531501T patent/DE69531501T3/de not_active Expired - Lifetime
- 1995-11-02 EP EP95935550A patent/EP0789587B2/en not_active Expired - Lifetime
- 1995-11-02 DK DK95935550T patent/DK0789587T4/da active
-
2004
- 2004-01-30 CY CY0400008A patent/CY2423B1/xx unknown
-
2007
- 2007-03-27 JP JP2007083117A patent/JP4871770B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-21 JP JP2010236921A patent/JP2011016850A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE69531501T3 (de) | 2008-11-13 |
| CA2204277A1 (en) | 1996-05-17 |
| EP0789587B1 (en) | 2003-08-13 |
| EP2204185A1 (en) | 2010-07-07 |
| EP1312377A3 (en) | 2004-02-04 |
| DK0789587T3 (da) | 2003-12-01 |
| JP2007169302A (ja) | 2007-07-05 |
| JP4871770B2 (ja) | 2012-02-08 |
| GB9422096D0 (en) | 1994-12-21 |
| JP2011016850A (ja) | 2011-01-27 |
| ES2204967T3 (es) | 2004-05-01 |
| ATE246936T1 (de) | 2003-08-15 |
| CA2689871A1 (en) | 1996-05-17 |
| WO1996014086A1 (en) | 1996-05-17 |
| EP0789587B2 (en) | 2008-04-02 |
| US6251401B1 (en) | 2001-06-26 |
| EP1312377A2 (en) | 2003-05-21 |
| DE69531501T2 (de) | 2004-06-24 |
| EP2204185A8 (en) | 2010-10-27 |
| DE69531501D1 (de) | 2003-09-18 |
| PT789587E (pt) | 2003-12-31 |
| CY2423B1 (en) | 2004-11-12 |
| JP3989951B2 (ja) | 2007-10-10 |
| EP0789587A1 (en) | 1997-08-20 |
| DK0789587T4 (da) | 2008-08-04 |
| JPH10509701A (ja) | 1998-09-22 |
| ES2204967T5 (es) | 2008-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2204277C (en) | Combined meningitis vaccine | |
| Fries et al. | Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults | |
| CA2264735C (en) | Neisseria meningitidis serogroup b glycoconjugates and methods of using the same | |
| Anderson et al. | Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults | |
| FERRECCIO et al. | The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age | |
| US4601903A (en) | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease | |
| Lepow et al. | Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age | |
| MacLennan et al. | Salmonella combination vaccines: moving beyond typhoid | |
| Käyhty | Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines | |
| Rietschel et al. | Pyrogenicity and immunogenicity of lipid A complexed with bovine serum albumin or human serum albumin | |
| AU5526190A (en) | A method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same | |
| JP2005506322A (ja) | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種 | |
| Pichichero et al. | Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussisvs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18-to 24-month old children | |
| KR100289224B1 (ko) | 조합 소아과 백신 조성물 | |
| Vella et al. | Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (Meningococcal protein conjugate)(PedvaxHIBTM) | |
| Joshi et al. | Meningococcal polysaccharide vaccines: A review | |
| Devi et al. | Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys | |
| HK1056503A (en) | Combined meningitis vaccine | |
| HK1143954A (en) | Combined meningitis vaccine | |
| Fattom | Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man | |
| Griffiss et al. | Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults | |
| McNeely et al. | Effect of individual conjugate dose on immunogenicity of type 6B pneumococcal polysaccharide–N. meningitidis outer membrane protein complex conjugate vaccines in infant rhesus monkeys | |
| Arndt et al. | Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae | |
| Gotschlich | Immune response to the meningococcal group-specific polysaccharides | |
| Scheifele et al. | Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141103 |